

NAME	REFERENCE	FINAL AMOUNT	CHEMISTRY
siRNA Negative control	SR-CLIV000-005	5 nmoles of duplex / tube	RNA
1 siRNA negative control duplex is made of two complementary strands			
Antisense strand	dTdT 3' overhang		
Sense strand	dTdT 3' overhang		
MODIFICATIONS 5' OR 3'			
None			
PURIFICATION		QC STATUS	
Purification process for in-vivo oligos		Passed	

DELIVERY CONDITION
Shipped lyophilized Additional reagent supplied : 1 ml RNase-free Water
RECONSTITUTION
To make up to 100 μ M concentration, add 50.0 μ l of recommended buffer. To make up to 20 μ M concentration, add 250.0 μ l of recommended buffer. To make up to 5 μ M concentration, add 1.00 ml of recommended buffer.
STORAGE CONDITION
Store siRNAs (and RNA oligos in general) as a dry pellet at -20°C (or preferably -70°C) in a non-frost free freezer until ready to use. Once resuspended in RNase-free buffer, store at -70°C and avoid contact with RNases. siRNA should be resuspended to a convenient stock concentration (e.g. 50 μ M), and stored in small aliquots to avoid multiple freeze thaw cycles. When stored under these conditions and using good RNase-free technique, they typically remain stable for 6 months or more. For long-term storage, siRNA oligos should be kept dried.

DESCRIPTION
The Negative Control siRNAs can be used to demonstrate that the transfection does not induce nonspecific effects on gene expression.
The Negative Control siRNAs developed by Eurogentec are comprised of two strands of complementary RNA bases with 3' dTdT overhangs. These proprietary sequences have no significant homology to any known eukaryotic gene.
The Control siRNA duplex negative control in vivo is purified according to our in-vivo purification process which includes HPLC purification, desalting, sterile filtration and lyophilization. The specific production process has been endotoxin tested in order to ensure in-vivo oligonucleotides are suitable for animal research. Endotoxins were undetectable using a chromogenic LAL endotoxin assay.
<i>Disclaimers and trademarks:</i> RNA interference is licensed under European Patents 1144623, 1214945 and foreign equivalents from Alnylam Pharmaceuticals, Inc., Cambridge, USA and is provided only for use in academic and commercial research (excluding the evaluation or characterization of this product as the potential basis for a siRNA-based drug) and not for any other commercial purposes. Information about licenses for commercial use (including discovery and development of siRNA-based drugs) is available from Alnylam Pharmaceuticals, Inc., 300 Third Street, Cambridge, MA 02142, USA.

TECHNICAL SUPPORT		
If you have any questions feel free to contact us ✉ oligo@eurogentec.com		
<table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> EUROPE Kaneka Eurogentec S.A. Liège Science Park Rue Bois Saint-Jean 5 - 4102 SERAING BELGIUM Tel: +32(0)4 372 74 00 - Fax: +32(0)4 264 07 88 E-mail: info@eurogentec.com Web: www.eurogentec.com RPM Liège T.V.A.-(BE)-0427.348.346 </td> <td style="width: 50%; vertical-align: top;"> NORTH AMERICA EGT North America, Inc. 34801 Campus Drive - Fremont, CA 94555 Tel.: +1 (510) 896 -1350 * Fax: +1 (510) 791-9572 E-mail: info@eurogentec.com Web: www.eurogentec.com </td> </tr> </table>	EUROPE Kaneka Eurogentec S.A. Liège Science Park Rue Bois Saint-Jean 5 - 4102 SERAING BELGIUM Tel: +32(0)4 372 74 00 - Fax: +32(0)4 264 07 88 E-mail: info@eurogentec.com Web: www.eurogentec.com RPM Liège T.V.A.-(BE)-0427.348.346	NORTH AMERICA EGT North America, Inc. 34801 Campus Drive - Fremont, CA 94555 Tel.: +1 (510) 896 -1350 * Fax: +1 (510) 791-9572 E-mail: info@eurogentec.com Web: www.eurogentec.com
EUROPE Kaneka Eurogentec S.A. Liège Science Park Rue Bois Saint-Jean 5 - 4102 SERAING BELGIUM Tel: +32(0)4 372 74 00 - Fax: +32(0)4 264 07 88 E-mail: info@eurogentec.com Web: www.eurogentec.com RPM Liège T.V.A.-(BE)-0427.348.346	NORTH AMERICA EGT North America, Inc. 34801 Campus Drive - Fremont, CA 94555 Tel.: +1 (510) 896 -1350 * Fax: +1 (510) 791-9572 E-mail: info@eurogentec.com Web: www.eurogentec.com	